Free Trial
NASDAQ:ADPT

Adaptive Biotechnologies Q3 2025 Earnings Report

Adaptive Biotechnologies logo
$17.22 +0.06 (+0.35%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$17.11 -0.11 (-0.61%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Adaptive Biotechnologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$58.76 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adaptive Biotechnologies Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Adaptive Biotechnologies Earnings Headlines

Robinhood warning
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT) is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine.

Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents.

Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.

View Adaptive Biotechnologies Profile

More Earnings Resources from MarketBeat